These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 18581464)

  • 1. Nifedipine versus carvedilol in the treatment of de novo arterial hypertension after liver transplantation: results of a controlled clinical trial.
    Galioto A; Semplicini A; Zanus G; Fasolato S; Sticca A; Boccagni P; Frigo AC; Cillo U; Gatta A; Angeli P
    Liver Transpl; 2008 Jul; 14(7):1020-8. PubMed ID: 18581464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between nifedipine and carvedilol in the treatment of de novo arterial hypertension after liver transplantation: preliminary results of a controlled clinical trial.
    Galioto A; Angeli P; Guarda S; Burra P; Zanus G; Fasolato S; Fagiuoli S; Sticca A; Semplicini A; Sartori M; Carraro A; Boccagni P; Cillo U; Gatta A
    Transplant Proc; 2005 Mar; 37(2):1245-7. PubMed ID: 15848684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidative stress and TGFbeta in kidney-transplanted patients with cyclosporin-induced hypertension. Effect of carvedilol and nifedipine.
    Calò L; Giacon B; Davis PA; Pagnin E; Piccin A; Riegler P; Huber W; Antonello A; Semplicini A
    Clin Nephrol; 2002 Aug; 58(2):103-10. PubMed ID: 12227681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled-release carvedilol in the treatment of essential hypertension.
    Weber MA; Sica DA; Tarka EA; Iyengar M; Fleck R; Bakris GL
    Am J Cardiol; 2006 Oct; 98(7A):32L-38L. PubMed ID: 17023230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension.
    Henderson LS; Tenero DM; Baidoo CA; Campanile AM; Harter AH; Boyle D; Danoff TM
    Am J Cardiol; 2006 Oct; 98(7A):17L-26L. PubMed ID: 17023228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients.
    Bell DS; Bakris GL; McGill JB
    Diabetes Obes Metab; 2009 Mar; 11(3):234-8. PubMed ID: 18564334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of carvedilol and nifedipine in patients with essential hypertension and non-insulin-dependent diabetes mellitus.
    Albergati F; Paternó E; Venuti RP; Boeri D; Lombardo I; Semino S; Viviani GL; Adezati L
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S86-9. PubMed ID: 1378156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of the coadministration of carvedilol and nifedipine sustained-release in the treatment of essential hypertension.
    Juttmann JR; de Vries Robles P; Venuti RP
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S134-7. PubMed ID: 1378141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of carvedilol as third-line add-on therapy on blood pressure and glucose metabolism in type 2 diabetic patients with chronic renal disease stage 3 and above.
    Yasuda G; Yatsu K; Yamamoto Y; Hirawa N
    Kidney Blood Press Res; 2012; 36(1):131-8. PubMed ID: 23095799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Use of carvedilol compared to nifedipine in the treatment of mild and moderate essential arterial hypertension].
    Plavnik FL; Freitas AF; Portela JE; Dantas M; Spritzer T; Kohlmann NE; Spritzer N; Furtado MR; Kohlmann O
    Arq Bras Cardiol; 1994 Nov; 63(5):405-8. PubMed ID: 7611920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of carvedilol, slow-release nifedipine, and atenolol in the management of essential hypertension.
    Hall S; Prescott RI; Hallman RJ; Dixon S; Harvey RE; Ball SG
    J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S35-8. PubMed ID: 1721977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antihypertensive effects on blood pressure at rest and during exercise of calcium antagonists, beta-receptor blockers, and their combination in hypertensive patients.
    Franz IW; Wiewel D
    J Cardiovasc Pharmacol; 1984; 6 Suppl 7():S1037-42. PubMed ID: 6085363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial).
    Di Lenarda A; Remme WJ; Charlesworth A; Cleland JG; Lutiger B; Metra M; Komajda M; Torp-Pedersen C; Scherhag A; Swedberg K; Poole-Wilson PA;
    Eur J Heart Fail; 2005 Jun; 7(4):640-9. PubMed ID: 15921806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of moderate to severe hypertension and proteinuria by nifedipine retard and perindopril after renal transplantation.
    Grekas D; Dioudis C; Kalevrosoglou I; Papoulidou F; Goutsaridis N; Alivanis P; Tourkantonis A
    Clin Nephrol; 1995 Nov; 44(5):299-302. PubMed ID: 8605709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study.
    Rouleau JL; Roecker EB; Tendera M; Mohacsi P; Krum H; Katus HA; Fowler MB; Coats AJ; Castaigne A; Scherhag A; Holcslaw TL; Packer M;
    J Am Coll Cardiol; 2004 Apr; 43(8):1423-9. PubMed ID: 15093878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.
    Miranda RD; Mion D; Rocha JC; Kohlmann O; Gomes MA; Saraiva JF; Amodeo C; Filho BL
    Clin Ther; 2008 Sep; 30(9):1618-28. PubMed ID: 18840367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of urapidil or metoprolol to the treatment of hypertensive non-responders to nifedipine monotherapy: efficacy and metabolic effects. Italian Urapidil Study Group.
    Zanchetti A
    Blood Press Suppl; 1995; 3():38-46. PubMed ID: 8535541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antihypertensive treatment with a vasodilating beta-blocker, carvedilol, in chronic hemodialysis patients.
    Deetjen A; Heidland A; Pangerl A; Meyer-Sabellek W; Schaefer RM
    Clin Nephrol; 1995 Jan; 43(1):47-52. PubMed ID: 7697935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of carvedilol on portal hypertension depends on the degree of endothelial activation and inflammatory changes.
    Bruha R; Vitek L; Petrtyl J; Lenicek M; Urbanek P; Zelenka J; Jachymova M; Svestka T; Kalab M; Dousa M; Marecek Z
    Scand J Gastroenterol; 2006 Dec; 41(12):1454-63. PubMed ID: 17101577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of carvedilol in severe hypertension.
    Ogihara T; Yoshinaga K; Kamahara Y; Ikeda M; Goto Y; Arakawa K; Iimura I; Ishii M; Kokubu T; Takeda T
    J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S69-72. PubMed ID: 1721983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.